期刊
BIOLOGICALS
卷 39, 期 4, 页码 195-204出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biologicals.2011.05.004
关键词
Carrier protein; Conjugate vaccine; Cross-reacting material 197; Diptheria toxin; Diphtheria toxoid; Cross-reactive material 197
资金
- Novartis Vaccines and Diagnostics
The biochemical and biological characteristics of CRM197 are reviewed. Polysaccharide protein conjugate vaccines represent an important technological advancement that allowed for protection against dangerous diseases in vulnerable populations such as infants. The first carrier proteins, diphtheria and tetanus toxoids, were chosen in the context of an extensive body of information describing their immunogenicity and safety profiles in clinical use. These carriers perform well, and they require detoxification. A non-toxic mutant of diphtheria toxin, cross-reacting material 197 (CRM197), is a useful carrier protein with several manufacturing and other potential advantages over toxoids. For over a decade, several important and widely used routine childhood glycoconjugate vaccines against serious illnesses, including Haemophilus influenzae type b and pneumococcal disease, have employed CRM197 as carrier protein. Additional clinical applications of CRM197, as in chemotherapy, also exist. (C) 2011 The International Alliance for Biologicals. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据